PATH Stock Under Pressure As UBS Trims Price Target

UiPath Inc. stocks have been trading up by 6.27 percent amid upbeat sentiment on expanding AI automation demand.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PATH

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

UBS lowered its price target on UiPath from $13 to $12, keeping a Neutral stance.
Street consensus on PATH remains a Hold rating with muted conviction.
The average Wall Street target of about $13.47 still sits above the recent $10.81 price.
PATH trades below consensus targets, drawing interest from value‑minded and contrarian traders.

Live Update At 16:01:37 EDT: On Friday, July 24, 2026 UiPath Inc. stock [NYSE: PATH] is trending up by 6.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

UiPath Inc. has grown from a hot automation story to a real business with real cash flows, and the numbers show it. PATH generated about $1.61B in revenue over the last year, with a strong 83% gross margin. That means most of each dollar of sales stays in the business after direct costs, which is what software traders want to see.

Profitability is still a work in progress, but it is moving the right way. Recent quarterly revenue of $418.4M produced operating income of $28M and net income of $22.5M, equal to $0.04 per share. On a trailing basis, PATH sports a price‑to‑earnings ratio near 17, and a price‑to‑sales ratio around 3.2, which is modest compared with many AI‑linked names.

More Breaking News

The balance sheet gives PATH breathing room. Cash and short‑term investments total roughly $1.31B against very low debt — long‑term debt is only about $72M, and total debt to equity sits near 0.04. Current and quick ratios of 2.3 and 1.9 show UiPath can cover near‑term bills without stress. For traders, that means fundamental risk of a cash crunch is low, even if the chart stays volatile.

Why Traders Are Watching PATH After The UBS Target Cut

The latest catalyst around PATH is not a blowout earnings print or a flashy AI product. It is a quiet, but important, move from UBS. The firm trimmed its UiPath price target from $13 to $12 while keeping a Neutral rating. That may sound minor, yet for active traders it sends a clear message: expectations are cooling.

At the same time, the broader Street still pegs PATH as a Hold with a mean target near $13.47, versus the recent $10.81 area. That gap tells you something different. Analysts are cautious, but they are not throwing in the towel. UiPath still shows implied upside on paper, even after the target cut.

On the chart, PATH has been sliding from the $12s this month down toward $10–$11. The recent daily candles show failed pushes into the low $12s followed by heavy selling, with the stock closing at $10.84 on 2026/07/24. Intraday action tells the same story. PATH dipped near $10.37 in the morning, then ground higher to finish just under $10.85, a controlled bounce but far from a trend reversal.

For short‑term traders, that combination — lowered targets, Hold ratings, and a battered chart — often creates two types of setups. Breakout traders watch for reclaim levels around $11.50–$12 where prior support turned into resistance. Mean‑reversion and contrarian traders look at PATH trading below the $13‑plus consensus and scout for oversold bounces, while still respecting the downside momentum.

Conclusion

UiPath sits at a crossroads. Fundamentally, PATH has what many software names lack: solid gross margins, positive free cash flow of about $129M last quarter, and over $600M in cash on hand. Leverage is tiny, and returns on capital are trending higher, with recent ROIC figures in the low‑to‑mid teens. On paper, that supports the idea behind the $13.47 Street target, even after UBS nudged its own PATH target down to $12.

But price action always tells the truth for traders. PATH has been locked in a downtrend from the $12s to the low $10s, and a Neutral stance from UBS signals that big Wall Street desks are in “prove it” mode. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” Until UiPath shows stronger, sustained earnings growth or a technical base, many funds will likely stay on the sidelines, which keeps volatility in play for active traders.

For day and swing traders, the job now is simple: map the key levels around $10 support and the $11.50–$12 resistance zone, watch volume, and react — not predict. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your discipline. Cut losses quickly, focus on predictable patterns, and let the best setups come to you.” PATH is giving plenty of data; it is up to traders to manage risk first and treat every trade as a lesson, not a promise.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!